up-arrow
arrow_back

DSP Healthcare Fund

DSP Healthcare Fund

share icon

Benchmark: S&P BSE HEALTHCARE (TRI) info icon

1.48 lakh people have invested in this fund

View performance details

Return:

This fund

18.00%

S&P BSE HEALTHCARE (TRI)

14.30%

NIFTY 50 TRI

14.15%

Invested

Earning

This fund

18.00%

S&P BSE HEALTHCARE (TRI)

14.30%

NIFTY 50 TRI

14.15%

team 1.48 lakh people have invested in this fund as of

This is an Equity Sectoral/Thematic, Pharma fund with S&P BSE HEALTHCARE (TRI) as its benchmark. The risk level for this fund is categorized as Very High Risk.

Total AUM

2,318.65 crores as of Feb 29, 2024

Age of Fund

5 years 3 months since Nov 30, 2018

Expense Ratio

1.98% as of Mar 28, 2024

Exit Load

0.5% If redeemed between 0 - 1 Months

Ideal holding period

10 Years+

Holdings

as of Feb 29, 2024

Sun Pharmaceutical Industries Limited

13.87%

Cipla Limited

8.20%

IPCA Laboratories Limited

8.01%

Lupin Limited

7.64%

Suven Pharmaceuticals Limited

7.60%

Alembic Pharmaceuticals Limited

5.94%

Apollo Hospitals Enterprise Limited

4.90%

Small Cap

34.70%

Large Cap

29.30%

Mid Cap

24.20%

Uncategorized

11.90%

Pharmaceuticals & Biotechnology

75.60%

Healthcare Services

13.80%

Healthcare Equipment & Supplies

7.00%

Insurance

1.80%

Retailing

0.60%

Rolling Returns

Bars show distribution of returns in given range for selected time period.

View performance details

Things to know before you invest

show iconhide icon

What is in DSP Healthcare Fund?

  1. This thematic fund invests in established & upcoming companies in the pharmaceutical & healthcare space in India and internationally (primarily, the United States).
  2. It can have up to 25% allocation to global stocks to provide access to sectors less developed or available in India.
  3. It considers companies who 'help people get well soon' across the healthcare spectrum- including pharmaceuticals, hospitals, diagnostics etc.
  1. Offers the potential to grow your wealth & 'earn big' returns if this theme does well (a high-risk, high-return strategy).
  2. Favourable sector dynamics- Rising income levels, increasing health-consciousness, government policies means an increase in healthcare spending, so companies in this space could do well.
  3. The up to 25% international exposure with low correlation to Indian healthcare companies means healthy diversification.
  4. Can help you beat the impact of rising prices over the long-term.
  5. Can be a suitable choice for tactical allocation.
  1. Consider this fund if you
    • Are an experienced investor with a well-set core portfolio & know what you're doing.
    • Are looking to tactically allocate 10-15% of your overall portfolio to very high-risk opportunities.
    • Understand that there is very high risk involved in this category of funds in the quest for high returns.
    • Have the patience and sectoral understanding to 'extract value' from changing sector cycles.
  1. This is a sectoral/ thematic fund, therefore its NAV is likely to fluctuate a lot more than diversified equity funds.
  2. Please do not use recent or past returns as the only criteria to evaluate this fund.
  3. Healthcare fund carries Very High Risk.

Fund managers:

Chirag Dagli

Chirag Dagli

Total work experience of 22 years. Managing this fund since December 2020
Total work experience of 22 years. Managing this fund since December 2020

right arrow iconSee funds managed by him

right arrow iconSee his investing philosophy

Jay Kothari

Jay Kothari

Total work experience of 18 years. Managing this fund since November 2018
Total work experience of 18 years. Managing this fund since November 2018

right arrow iconSee funds managed by him

Portfolio

Prescribed asset allocation: 80% - 100% Equity and equity related securities of pharmaceutical and healthcare companies , 0% - 20% Equity and Equity related securities of other Companies , 0% - 20% Debt, securitized debt and Money Market Securities , 0% - 10% Units of REITs & InvITs

Current Allocation

as of Feb 29, 2024

Top holdings

Sun Pharmaceutical Industries Limited

13.87%

Cipla Limited

8.20%

IPCA Laboratories Limited

8.01%

Lupin Limited

7.64%

Suven Pharmaceuticals Limited

7.60%

Allocation by Market Cap

Small Cap

34.70%

Large Cap

29.30%

Mid Cap

24.20%

Uncategorized

11.90%

Top Sectors

Pharmaceuticals & Biotechnology

74.21%

Healthcare Services

13.59%

Healthcare Equipment & Supplies

6.88%

Insurance

1.78%

Mutual-funds

1.11%

Top holdings

TREPS / Reverse Repo Investments / Corporate Debt Repo

1.87%

Cash & cash equivalents

-0.02%

Credit rating profile

Cash & Equivalent

101.60%

Instrument break-up

TREPS

100.00%


Indicators

Portfolio turnover ratio

0.14 last 12 months

Standard Deviation

14.88 %

Sharpe Ratio

0.89

Beta

0.87

R-Squared

88.42 %

Compare Performance

Performance highlights over last

for

investment

Cumulative returns on

Annual returns

Current value

Min CAGR:
MedianCAGR:
Max CAGR:

Good Returns

return card icon

Negative Returns

return card icon

vs Fixed Deposit

return card icon

vs Category

return card icon

vs Benchmark

return card icon

  • Historical Returns (As per SEBI format)as of with investment of10,000

This fund S&P BSE HEALTHCARE (TRI) ^ NIFTY 50 TRI #
CAGR Current Value CAGR Current Value CAGR Current Value

Income distribution Cum Capital Withdrawal (IDCW) Distributed

Record Date IDCW per unit NAV Before NAV After

Chart type

Invested as

Invested Amount

Invested since

This fund

Vs

S&P BSE HEALTHCARE (TR

NIFTY 50 TRI

Gold

PPF

Funds Annual returns Current Value Absolute Growth

Chart type:

Invested as

Invested Amount

Invested period

Funds Minimum Median Maximum % times -ve returns % times returns > 7%

Date of allotment: Nov 30, 2018.

Period for which fund's performance has been provided is computed based on last day of the month-end preceding the date of advertisement

Different plans shall have a different expense structure. The performance details provided herein are of Regular Plan.

Since inception returns have been calculated from the date of allotment till June 30, 2021

Past performance may or may not be sustained in future and should not be used as a basis for comparison with other investments

Rolling returns have been calculated based on returns from regular plan growth option.

^ Fund Benchmark # Standard Benchmark

Fund Details

Fund Details

Investment Objective

The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
There is no assurance that the investment objective of the Scheme will be realized

Fund Type

Equity – Sectoral/Thematic
Pharma

An open ended equity scheme investing in healthcare and pharmaceutical sector

Riskometer

Level of Risk in the fund

View details

Minimum Investment

Rs.  100 Lumpsum
Rs.  100 SIP– 12 instalments
Rs.  100 Minimum Additional Purchase

team 1.48 lakh peoplehave invested in this fund as of